Common activation mechanism of class A GPCRs

Class A G-protein-coupled receptors (GPCRs) influence virtually every aspect of human physiology. Understanding receptor activation mechanism is critical for discovering novel therapeutics since about one-third of all marketed drugs target members of this family. GPCR activation is an allosteric pro...

Full description

Bibliographic Details
Main Authors: Qingtong Zhou, Dehua Yang, Meng Wu, Yu Guo, Wanjing Guo, Li Zhong, Xiaoqing Cai, Antao Dai, Wonjo Jang, Eugene I Shakhnovich, Zhi-Jie Liu, Raymond C Stevens, Nevin A Lambert, M Madan Babu, Ming-Wei Wang, Suwen Zhao
Format: Article
Language:English
Published: eLife Sciences Publications Ltd 2019-12-01
Series:eLife
Subjects:
Online Access:https://elifesciences.org/articles/50279
id doaj-1fd7d071b55047e5a53a68b7fcb67b21
record_format Article
collection DOAJ
language English
format Article
sources DOAJ
author Qingtong Zhou
Dehua Yang
Meng Wu
Yu Guo
Wanjing Guo
Li Zhong
Xiaoqing Cai
Antao Dai
Wonjo Jang
Eugene I Shakhnovich
Zhi-Jie Liu
Raymond C Stevens
Nevin A Lambert
M Madan Babu
Ming-Wei Wang
Suwen Zhao
spellingShingle Qingtong Zhou
Dehua Yang
Meng Wu
Yu Guo
Wanjing Guo
Li Zhong
Xiaoqing Cai
Antao Dai
Wonjo Jang
Eugene I Shakhnovich
Zhi-Jie Liu
Raymond C Stevens
Nevin A Lambert
M Madan Babu
Ming-Wei Wang
Suwen Zhao
Common activation mechanism of class A GPCRs
eLife
allostery
GPCR
activation mechanism
genetic diseases
signal transduction
drug discovery
author_facet Qingtong Zhou
Dehua Yang
Meng Wu
Yu Guo
Wanjing Guo
Li Zhong
Xiaoqing Cai
Antao Dai
Wonjo Jang
Eugene I Shakhnovich
Zhi-Jie Liu
Raymond C Stevens
Nevin A Lambert
M Madan Babu
Ming-Wei Wang
Suwen Zhao
author_sort Qingtong Zhou
title Common activation mechanism of class A GPCRs
title_short Common activation mechanism of class A GPCRs
title_full Common activation mechanism of class A GPCRs
title_fullStr Common activation mechanism of class A GPCRs
title_full_unstemmed Common activation mechanism of class A GPCRs
title_sort common activation mechanism of class a gpcrs
publisher eLife Sciences Publications Ltd
series eLife
issn 2050-084X
publishDate 2019-12-01
description Class A G-protein-coupled receptors (GPCRs) influence virtually every aspect of human physiology. Understanding receptor activation mechanism is critical for discovering novel therapeutics since about one-third of all marketed drugs target members of this family. GPCR activation is an allosteric process that couples agonist binding to G-protein recruitment, with the hallmark outward movement of transmembrane helix 6 (TM6). However, what leads to TM6 movement and the key residue level changes of this movement remain less well understood. Here, we report a framework to quantify conformational changes. By analyzing the conformational changes in 234 structures from 45 class A GPCRs, we discovered a common GPCR activation pathway comprising of 34 residue pairs and 35 residues. The pathway unifies previous findings into a common activation mechanism and strings together the scattered key motifs such as CWxP, DRY, Na+ pocket, NPxxY and PIF, thereby directly linking the bottom of ligand-binding pocket with G-protein coupling region. Site-directed mutagenesis experiments support this proposition and reveal that rational mutations of residues in this pathway can be used to obtain receptors that are constitutively active or inactive. The common activation pathway provides the mechanistic interpretation of constitutively activating, inactivating and disease mutations. As a module responsible for activation, the common pathway allows for decoupling of the evolution of the ligand binding site and G-protein-binding region. Such an architecture might have facilitated GPCRs to emerge as a highly successful family of proteins for signal transduction in nature.
topic allostery
GPCR
activation mechanism
genetic diseases
signal transduction
drug discovery
url https://elifesciences.org/articles/50279
work_keys_str_mv AT qingtongzhou commonactivationmechanismofclassagpcrs
AT dehuayang commonactivationmechanismofclassagpcrs
AT mengwu commonactivationmechanismofclassagpcrs
AT yuguo commonactivationmechanismofclassagpcrs
AT wanjingguo commonactivationmechanismofclassagpcrs
AT lizhong commonactivationmechanismofclassagpcrs
AT xiaoqingcai commonactivationmechanismofclassagpcrs
AT antaodai commonactivationmechanismofclassagpcrs
AT wonjojang commonactivationmechanismofclassagpcrs
AT eugeneishakhnovich commonactivationmechanismofclassagpcrs
AT zhijieliu commonactivationmechanismofclassagpcrs
AT raymondcstevens commonactivationmechanismofclassagpcrs
AT nevinalambert commonactivationmechanismofclassagpcrs
AT mmadanbabu commonactivationmechanismofclassagpcrs
AT mingweiwang commonactivationmechanismofclassagpcrs
AT suwenzhao commonactivationmechanismofclassagpcrs
_version_ 1721458707636682752
spelling doaj-1fd7d071b55047e5a53a68b7fcb67b212021-05-05T18:12:10ZengeLife Sciences Publications LtdeLife2050-084X2019-12-01810.7554/eLife.50279Common activation mechanism of class A GPCRsQingtong Zhou0https://orcid.org/0000-0001-8124-3079Dehua Yang1https://orcid.org/0000-0003-3028-3243Meng Wu2Yu Guo3Wanjing Guo4Li Zhong5Xiaoqing Cai6Antao Dai7Wonjo Jang8Eugene I Shakhnovich9https://orcid.org/0000-0002-4769-2265Zhi-Jie Liu10https://orcid.org/0000-0001-7279-2893Raymond C Stevens11Nevin A Lambert12https://orcid.org/0000-0001-7550-0921M Madan Babu13Ming-Wei Wang14Suwen Zhao15https://orcid.org/0000-0001-5609-434XiHuman Institute, ShanghaiTech University, Shanghai, ChinaThe CAS Key Laboratory of Receptor Research, Shanghai Institute of Materia Medica, Chinese Academy of Sciences, Shanghai, China; University of Chinese Academy of Sciences, Beijing, China; The National Center for Drug Screening, Shanghai Institute of Materia Medica, Chinese Academy of Sciences, Shanghai, ChinaiHuman Institute, ShanghaiTech University, Shanghai, China; University of Chinese Academy of Sciences, Beijing, China; School of Life Science and Technology, ShanghaiTech University, Shanghai, ChinaiHuman Institute, ShanghaiTech University, Shanghai, China; University of Chinese Academy of Sciences, Beijing, China; School of Life Science and Technology, ShanghaiTech University, Shanghai, ChinaThe CAS Key Laboratory of Receptor Research, Shanghai Institute of Materia Medica, Chinese Academy of Sciences, Shanghai, China; University of Chinese Academy of Sciences, Beijing, China; The National Center for Drug Screening, Shanghai Institute of Materia Medica, Chinese Academy of Sciences, Shanghai, ChinaThe CAS Key Laboratory of Receptor Research, Shanghai Institute of Materia Medica, Chinese Academy of Sciences, Shanghai, China; University of Chinese Academy of Sciences, Beijing, China; The National Center for Drug Screening, Shanghai Institute of Materia Medica, Chinese Academy of Sciences, Shanghai, ChinaThe CAS Key Laboratory of Receptor Research, Shanghai Institute of Materia Medica, Chinese Academy of Sciences, Shanghai, China; The National Center for Drug Screening, Shanghai Institute of Materia Medica, Chinese Academy of Sciences, Shanghai, ChinaThe CAS Key Laboratory of Receptor Research, Shanghai Institute of Materia Medica, Chinese Academy of Sciences, Shanghai, China; The National Center for Drug Screening, Shanghai Institute of Materia Medica, Chinese Academy of Sciences, Shanghai, ChinaDepartment of Pharmacology and Toxicology, Medical College of Georgia, Augusta University, Augusta, United StatesDepartment of Chemistry and Chemical Biology, Harvard University, Cambridge, United StatesiHuman Institute, ShanghaiTech University, Shanghai, China; School of Life Science and Technology, ShanghaiTech University, Shanghai, ChinaiHuman Institute, ShanghaiTech University, Shanghai, China; School of Life Science and Technology, ShanghaiTech University, Shanghai, ChinaDepartment of Pharmacology and Toxicology, Medical College of Georgia, Augusta University, Augusta, United StatesMRC Laboratory of Molecular Biology, Cambridge, United KingdomThe CAS Key Laboratory of Receptor Research, Shanghai Institute of Materia Medica, Chinese Academy of Sciences, Shanghai, China; University of Chinese Academy of Sciences, Beijing, China; The National Center for Drug Screening, Shanghai Institute of Materia Medica, Chinese Academy of Sciences, Shanghai, China; School of Life Science and Technology, ShanghaiTech University, Shanghai, China; School of Pharmacy, Fudan University, Shanghai, ChinaiHuman Institute, ShanghaiTech University, Shanghai, China; School of Life Science and Technology, ShanghaiTech University, Shanghai, ChinaClass A G-protein-coupled receptors (GPCRs) influence virtually every aspect of human physiology. Understanding receptor activation mechanism is critical for discovering novel therapeutics since about one-third of all marketed drugs target members of this family. GPCR activation is an allosteric process that couples agonist binding to G-protein recruitment, with the hallmark outward movement of transmembrane helix 6 (TM6). However, what leads to TM6 movement and the key residue level changes of this movement remain less well understood. Here, we report a framework to quantify conformational changes. By analyzing the conformational changes in 234 structures from 45 class A GPCRs, we discovered a common GPCR activation pathway comprising of 34 residue pairs and 35 residues. The pathway unifies previous findings into a common activation mechanism and strings together the scattered key motifs such as CWxP, DRY, Na+ pocket, NPxxY and PIF, thereby directly linking the bottom of ligand-binding pocket with G-protein coupling region. Site-directed mutagenesis experiments support this proposition and reveal that rational mutations of residues in this pathway can be used to obtain receptors that are constitutively active or inactive. The common activation pathway provides the mechanistic interpretation of constitutively activating, inactivating and disease mutations. As a module responsible for activation, the common pathway allows for decoupling of the evolution of the ligand binding site and G-protein-binding region. Such an architecture might have facilitated GPCRs to emerge as a highly successful family of proteins for signal transduction in nature.https://elifesciences.org/articles/50279allosteryGPCRactivation mechanismgenetic diseasessignal transductiondrug discovery